Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in pediatric glucocorticoid-induced osteoporosis (Phase 3)
2016-003083-39Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glucocorticoid-induced osteoporosis (GIOP) and osteoporosis comparing Denosumab with Placebo (2 arms). Primary endpoint: Change in lumbar spine BMD Z-score at 12 months. Started Nov 2016; status: completed.
02
Drugs
denosumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)osteoporosis
Beyond the preview
Go deeper on 2016-003083-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003083-39.